The goal of this clinical trial is to learn if bezisterim can treat movement symptoms of Parkinson's disease in patients that are 45 to 80 years old, in generally good physical and mental health, and are nearing the need for treatment to relieve their symptoms but have not yet been prescribed any form of levodopa or drug with similar activity. The main questions it aims to answer are:
* Will bezisterim decrease movement symptoms of Parkinson's disease?
* What medical problems do participants have when taking bezisterim?
Researchers will compare the effects of bezisterim treatment to placebo (a look-alike substance that contains no drug) to see if bezisterim works to treat movement symptoms of Parkinson's disease.
Participants will
* have a physical examination that includes an electrocardiogram
* take drug or placebo twice daily for four months
* visit a clinical site or receive an at home visit seven times over the course of five months

开始日期2025-02-01

申办/合作机构

BioVie, Inc.

NCT05970575

/ Recruiting临床2期IIT

Open Label Phase IIa Study Evaluating the Safety and Efficacy of NE3107 in Improving Sleep and Fatigue in Subjects With Traumatic Brain Injury

This study seeks to measure changes in cognition through verbal and visual test procedures and changes in biomarkers of Traumatic Brain Injury and inflammatory and metabolic parameters.

开始日期2023-12-21

申办/合作机构

BioVie, Inc.

NCT05227820

/ Completed临床2期IIT

Anti-Inflammatory, Insulin-Sensitizing Agent for Treatment of Cognitive Decline Due to Degenerative Dementias

This study seeks to measure changes in cognition through verbal and visual test procedures and changes in biomarkers of Alzheimer's disease and inflammatory and metabolic parameters that can be measure in the central nervous system (CNS) with advanced neuroimaging techniques in patients treated with NE3107 (17a-ethynyl-androst-5-3b,7b,17b-triol).

开始日期2022-01-19

申办/合作机构

BioVie, Inc.

100 项与 Triolex 相关的临床结果

登录后查看更多信息

100 项与 Triolex 相关的转化医学

登录后查看更多信息

100 项与 Triolex 相关的专利（医药）

登录后查看更多信息

158

项与 Triolex 相关的文献（医药）

2024-07-26·Medicine

A phase 2, open-label study of anti-inflammatory NE3107 in patients with dementias

Article

作者: Jordan, Sheldon ; Mahdavi, Kennedy ; Goodenowe, Dayan ; Jordan, Kaya ; Rindner, Elisabeth ; Venkatraman, Victoria ; Zhang, Jeffrey ; Surya, Jean Rama ; Zielinski, Margaret ; Reading, Christopher ; Ahlem, Clarence ; Pourat, Bijan ; Palumbo, Joseph ; Becerra, Sergio ; Kuhn, Taylor ; Hofmeister, Kaitlyn ; Haroon, Jonathan

Background:Alzheimer’s disease (AD) is a progressive, multifactorial, neurodegenerative disorder affecting >6 million Americans. Chronic, low-grade neuroinflammation, and insulin resistance may drive AD pathogenesis. We explored the neurophysiological and neuropsychological effects of NE3107, an oral, anti-inflammatory, insulin-sensitizing molecule, in AD.Methods:In this phase 2, open-label study, 23 patients with mild cognitive impairment or mild dementia received 20-mg oral NE3107 twice daily for 3 months. Primary endpoints assessed changes from baseline in neurophysiological health and oxidative stress (glutathione level) using advanced neuroimaging analyses. Secondary endpoints evaluated changes from baseline in neuropsychological health using cognitive assessments, including the 11-item Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog11), Mini-Mental State Examination (MMSE), Montreal Cognitive Assessment, Clinical Dementia Rating, Quick Dementia Rating Scale, Alzheimer’s Disease Composite Score, and Global Rating of Change (GRC). Exploratory endpoints assessed changes from baseline in neuroinflammation biomarkers (tumor necrosis factor alpha, TNF-α) and AD (amyloid beta and phosphorylated tau [P-tau]).Results:NE3107 was associated with clinician-rated improvements in cerebral blood flow and functional connectivity within the brain. In patients with MMSE ≥ 20 (mild cognitive impairment to mild AD; n = 17), NE3107 was associated with directional, but statistically nonsignificant, changes in brain glutathione levels, along with statistically significant improvements in ADAS-Cog11 (P = .017), Clinical Dementia Rating (P = .042), Quick Dementia Rating Scale (P = .002), Alzheimer’s Disease Composite Score (P = .0094), and clinician-rated GRC (P < .001), as well as in cerebrospinal fluid P-tau levels (P = .034) and P-tau:amyloid beta 42 ratio (P = .04). Biomarker analyses also demonstrated directional, but statistically non-significant, changes in plasma TNF-α, consistent with the expected mechanism of NE3107. Importantly, we observed a statistically significant correlation (r = 0.59) between improvements in TNF-α levels and ADAS-Cog11 scores (P = .026) in patients with baseline MMSE ≥ 20.Conclusion:Our results indicate that in this study NE3107 was associated with what appear to be positive neurophysiological and neuropsychological findings, as well as evidence of improvement in biomarkers associated with neuroinflammation and AD in patients diagnosed with dementia. Our findings are consistent with previous preclinical and clinical observations and highlight a central role of neuroinflammation in AD pathogenesis.

2024-07-01·Molecular Neurobiology

A Synthetic Steroid 5α-Androst-3β, 5, 6β-triol Alleviates Radiation-Induced Brain Injury in Mice via Inhibiting GBP5/NF-κB/NLRP3 Signal Axis

Article

作者: Li, Shaojian ; Deng, Zhenhong ; Ma, Xueying ; Tang, Yamei ; Shi, Zhongshan ; Yuan, Mingjun ; Zhu, Xiaoqiu ; Chen, Yupin ; Zhong, Ke ; Song, Yu ; Yin, Wei ; Yang, Jingwen ; Huang, Yijun ; Liu, Kejia ; Chen, Sitai ; Xue, Ruiqi ; Hu, Xia

Radiotherapy for head and neck tumors can lead to a severe complication known as radiation-induced brain injury (RIBI). However, the underlying mechanism of RIBI development remains unclear, and limited prevention and treatment options are available. Neuroactive steroids have shown potential in treating neurological disorders. 5α-Androst-3β, 5, 6β-triol (TRIOL), a synthetic neuroprotective steroid, holds promise as a treatment candidate for RIBI patients. However, the neuroprotective effects and underlying mechanism of TRIOL on RIBI treatment are yet to be elucidated. In the present study, our findings demonstrate TRIOL's potential as a neuroprotective agent against RIBI. In gamma knife irradiation mouse model, TRIOL treatment significantly reduced brain necrosis volume, microglial activation, and neuronal loss. RNA-sequencing, immunofluorescence, real-time quantitative polymerase chain reaction, siRNA transfection, and western blotting techniques revealed that TRIOL effectively decreased microglial activation, proinflammatory cytokine release, neuron loss, and guanylate-binding protein 5 (GBP5) expression, along with its downstream signaling pathways NF-κB and NLRP3 activation in vitro. In summary, TRIOL effectively alleviate RIBI by inhibiting the GBP5/NF-κB/NLRP3 signal axis, reducing microglia activation and pro-inflammation cytokines release, rescuing neuron loss. This study highlights the potential of TRIOL as a novel and promising therapy drug for RIBI treatment.

2024-06-01·Drug Testing and Analysis

New long‐standing metabolites of 17α‐methyltestosterone are detected in HepG2 cell in vitro metabolic model and in human urine

Article

作者: Chlapana, Fotini ; Georgakopoulos, Costas ; Angelis, Yiannis S ; Sakellariou, Panagiotis ; Kletsas, Dimitris ; Kiousi, Polyxeni ; Loui, Stella ; Kioukia-Fougia, Nassia ; Fragkaki, Argyro G ; Karnava, Sophia ; Goula, Olga

AbstractNovel metabolites of the anabolic androgenic steroid 17α‐methyltestosterone have been detected in HepG2 cell in vitro metabolic model and in human urine. Their detection was accomplished through targeted gas chromatography–(tandem) mass spectrometry analysis that has been based on microscale synthesized standards. The related synthesis and the gas chromatography–(tandem) mass spectrometry characterization of the analytical standards are described. All newly presented metabolites have a fully reduced steroid A‐ring with either an 17,17‐dimethyl‐18‐nor‐Δ13 structure or they have been further oxidized at position 16 of the steroid backbone. Metabolites with 17,17‐dimethyl‐18‐nor‐Δ13 structure may be considered as side products of phase II metabolic sulfation of the 17β‐hydroxy group of methyltestosterone or its reduced tetrahydro‐methyltestosterone metabolites 17α‐methyl‐5β‐androstane‐3α,17β‐diol and 17α‐methyl‐5α‐androstane‐3α,17β‐diol that produce the known epimeric 17β‐methyl‐5β‐androstane‐3α,17α‐diol and 17β‐methyl‐5α‐androstane‐3α,17α‐diol metabolites. The prospective of these new metabolites to increase detection time windows and improve identification was investigated by applying the World Anti‐doping Agency TD2021IDCR criteria. The new metabolites, presented herein, complement the current knowledge on the 17α‐methyltestosterone metabolism and in some cases can be used as additional long‐term markers in the frame of sport doping drug testing.

113

项与 Triolex 相关的新闻（医药）

2024-11-20

·GlobeNewswire-Health Care

BioVie to Present Design of Planned Phase 2 Study of Bezisterim for the Treatment of Long COVID at the Demystifying Long COVID International Conference

CARSON CITY, Nev., Nov. 20, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that an abstract on the design of its planned Phase 2 trial evaluating bezisterim in Long COVID has been accepted as a poster presentation at the Demystifying Long COVID International Conference, November 21st & 22nd 2024, in Barcelona Spain. The planned Phase 2 study, which is fully funded by a grant from the U.S. Department of Defense (DOD), is a double-blind, randomized (1:1), placebo-controlled, multicenter trial in approximately 200 patients to evaluate the safety, tolerability and potential efficacy of 3 months of treatment with bezisterim to reduce the neurocognitive symptoms associated with Long COVID. Details for the presentation are as follows: Title: A Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of Bezisterim (NE3107) in Adults with Long COVIDPoster number: 28Presentation date: November 21, 2024Presenter: Penelope Markham, Ph.D, Senior Vice President and Program Lead, Long COVID, BioVie Inc. About Long COVIDLong COVID is a condition in which symptoms of COVID-19, the acute respiratory disease caused by the SARS-CoV-2 virus, persist for an extended period of time, generally three months or more. Common symptoms include lingering loss of smell and taste, extreme fatigue, and “brain fog,” though persistent cardiovascular and respiratory problems, muscle weakness, and neurologic issues have also been documented. The Centers for Disease Control recently reported that 6.8% of adults in the United States (more than 17 million individuals) currently or previously have long COVID1 though a recent analysis using real world data estimates the prevalence could be as high as 22%2. The loss in quality of life and earnings and increased medical costs has an enormous economic impact estimated to be $3.7 trillion3. To date there are no non-pharmacological or pharmacological therapies proven effective for treatment of long COVID. Terms of the Department of Defense AwardThe work is supported by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, by a fully funded award in the amount of $13,137,150 through the Peer Reviewed Medical Research Program (PRMRP) under Award No. HT9425-24-1-0113. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the Department of Defense. About BioVie Inc. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Long COVID, Alzheimer's disease and Parkinson’s disease) and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of Long COVID. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com. References 1Ford ND, Agedew A, Dalton AF, Singleton J, Perrine CG, Saydah S. Notes from the Field: Long COVID Prevalence Among Adults — United States, 2022. MMWR Morb Mortal Wkly Rep 2024;73:135–136. DOI: http://dx.doi.org.libproxy1.nus.edu.sg/10.15585/mmwr.mm7306a4. 2 Azhir A et al. “Precision Phenotyping for Curating Research Cohorts of Patients with Unexplained Post-Acute Sequelae of COVID-19” Med DOI: 10.1016/j.medj.2024.10.009, in press 3Cutler, David M. 2022 The economic costs of Long COVID: An update. long_covid_update_7-22.pdf (harvard.edu) Forward-Looking StatementsThis press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. For Investor Relations Inquiries: Bruce Mackle Managing Director, LifeSci Advisors, LLC bmackle@lifesciadvisors.com For Media Relations Inquiries: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@elixirhealthpr.com

临床2期孤儿药快速通道

2024-11-12

·Pharmaceutical Technology

DMTs are major clinical research focus for Parkinson’s disease, analysis shows

The World Health Organisation estimated that over 8.5 million people had PD in 2019. Credit: LE Photo / Shutterstock. Pipeline treatments across the seven major markets (7MM: France, Germany, Italy, Spain, the UK, the US and Japan) reflect a growing research trend prioritising disease-modifying therapies (DMTs) and non-motor symptom therapies in the treatment of Parkinson’s disease, according to new research. The current therapeutic landscape for Parkinson’s is heavily genericised, exhibiting a notable lack of available neuroprotective treatments. However, Lorraine Palmer, pharmaceuticals analyst at GlobalData, says this is changing. “There are a total of 93 products in Phase I-III development within the 7MM for the treatment of Parkinson’s,” Palmer said. “66% of these are prospective neuroprotective agents or DMTs. These investigational agents target the key mechanisms that have been implicated in the pathophysiology of Parkinson’s, such as alpha-synuclein aggregation and neuroinflammation, with the goal of slowing disease progression.” GlobalData is Pharmaceutical Technology ’s parent company. DMTs look to be a particularly significant piece of the Parkinson’s puzzle, and key opinion leaders interviewed by GlobalData agreed on the need for further research focus, despite complications presented by the differing pathogenesis of Parkinson’s across patients. One of the neuroprotective and DMT agents in late-stage development is Annovis Bio’s Posiphen (buntanetap tartrate) . The drug is aimed at inhibiting alpha-synuclein, and it is currently in Phase III development in the US and five major European markets. Elsewhere, a Phase III trial in the US has been planned for BioVie’s Triolex (bezisterim) , which is an inhibitor of inflammatory mediators and is thought to offer neuroprotective potential. Palmer added: “26% of the pipeline DMTs in the pipeline target alpha-synuclein aggregation. This is a divisive mechanism of action, with some key opinion leaders holding high hopes and others expressing scepticism, highlighting the failure of Prothena and Roche’s prasinezumab to meet its primary endpoint in the Phase II PASADENA trial (NCT03100149) and safety concerns due to the role of alpha-synuclein in healthy functioning.” Alongside DMTs, treating non-motor symptoms is also becoming a key research focus, highlighted by analysis which shows that 3% of the pipeline is specifically targeting Parkinson’s disease dementia (experienced by up to 80% of people with Parkinson’s ) and Parkinson’s disease psychosis (experienced to some degree by between 20% and 40% of people with Parkinson’s ). Research development appears to be addressing a broader spectrum of Parkinson’s challenges, and there is interest in antiparkinsonian agents, dopamine agonists and treatments for Parkinson’s disease related dementia. It suggests that the industry is looking to improve both motor and non-motor symptoms, addressing the broader spectrum of challenges faced by Parkinson’s patients. Palmer concluded: “The distribution of the 93 pipeline agents in the 7MM underscores a strong emphasis on neuroprotective and disease-modifying treatments, demonstrating an industry-wide focus toward therapies that could potentially slow the progression of Parkinson’s.”

临床2期临床3期

2024-10-29

·GlobeNewswire-Health Care

BioVie Inc. Announces Closing of Registered Direct Offering

CARSON CITY, Nev., Oct. 29, 2024 (GLOBE NEWSWIRE) -- BioVie Inc. (Nasdaq: BIVI), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders, today announced the closing of its previously announced registered direct offering of 1,146,000 shares of its common stock priced at-the-market under Nasdaq rules at a price of $2.83 per share. The gross proceeds to the Company from the offering are $3,243,180, before deducting placement agent fees and offering expenses. The Company intends to use the net proceeds from the offering primarily for working capital and general corporate purposes. ThinkEquity acted as sole placement agent for the offering. The shares of common stock offered in the registered direct offering were offered and sold pursuant to a shelf registration statement on Form S-3 (File No. 333-274083), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on August 18, 2023 and declared effective on August 28, 2023. A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC and is available on its website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004. This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. About BioVie Inc. BioVie Inc. (NASDAQ: BIVI) is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders (Long COVID, Alzheimer's disease and Parkinson’s disease) and advanced liver disease. In neurodegenerative disease, the Company’s drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor, Nuclear factor- kB, and the associated neuroinflammation and insulin resistance but not ERK and NFkB homeostatic functions (e.g., insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of AD and PD. Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of Long COVID. In liver disease, the Company’s Orphan drug candidate BIV201 (continuous infusion terlipressin), with FDA Fast Track status, is being evaluated and discussed with guidance received from the FDA regarding the design of Phase 3 clinical testing of BIV201 for the reduction of further decompensation in participants with liver cirrhosis and ascites. The active agent is approved in the U.S. and in about 40 countries for related complications of advanced liver cirrhosis. For more information, visit www.bioviepharma.com. Forward-Looking Statements This press release contains forward-looking statements, which may be identified by words such as "expect," "look forward to," "anticipate" "intend," "plan," "believe," "seek," "estimate," "will," "project" or words of similar meaning. Although BioVie Inc. believes such forward-looking statements are based on reasonable assumptions, it can give no assurance that its expectations will be attained. Actual results may vary materially from those expressed or implied by the statements herein due to the Company's ability to successfully raise sufficient capital on reasonable terms or at all, available cash on hand and contractual and statutory limitations that could impair our ability to pay future dividends, our ability to complete our pre-clinical or clinical studies and to obtain approval for our product candidates, our ability to successfully defend potential future litigation, changes in local or national economic conditions as well as various additional risks, many of which are now unknown and generally out of the Company's control, and which are detailed from time to time in reports filed by the Company with the SEC, including quarterly reports on Form 10-Q, reports on Form 8-K and annual reports on Form 10-K. BioVie Inc. does not undertake any duty to update any statements contained herein (including any forward-looking statements), except as required by law. For Investor Relations Inquiries: Bruce Mackle Managing Director, LifeSci Advisors, LLC bmackle@lifesciadvisors.com For Media Relations Inquiries: Melyssa Weible Managing Partner, Elixir Health Public Relations mweible@elixirhealthpr.com

孤儿药快速通道

100 项与 Triolex 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05212

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
阿尔茨海默症	临床3期	美国	BioVie, Inc.	2021-08-05
多发性骨髓瘤	临床2期	美国	NeurMedix, Inc.	2022-08-10
前列腺癌	临床2期	美国	NeurMedix, Inc.	2022-08-10
帕金森病	临床2期	美国	BioVie, Inc.	2022-01-04
认知功能障碍	临床1期	美国	BioVie, Inc.	2022-01-19
类风湿关节炎	临床1期	美国	Harbor Therapeutics, Inc.	2008-07-01
溃疡性结肠炎	临床1期	美国	Harbor Therapeutics, Inc.	2008-02-01
2型糖尿病	临床1期	-	中国医药工业研究总院有限公司	-
2型糖尿病	临床1期	-	中国医药工业研究总院有限公司	-
溃疡性结肠炎	临床前	美国	Harbor Therapeutics, Inc.	2008-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05227820 (CTgov)	临床2期	阿尔茨海默症 \| 认知功能障碍	23	NE3107	積艱願衊憲齋範顧衊鏇(襯憲構鹽簾襯夢壓範醖) = 淵衊鏇繭觸齋膚鏇構醖齋艱鏇壓餘壓蓋鑰夢構 (簾鏇窪範築壓觸鹽憲廠, 廠淵蓋襯築繭鬱鬱觸簾 ~ 糧糧觸願鬱襯築築廠壓) 更多	-	2024-07-09
NCT04669028 (GlobeNewswire) 人工标引	临床3期	阿尔茨海默症	-	Bezisterim	糧積範襯憲鑰夢網繭鹹(鑰獵鹽獵餘夢淵窪衊窪) = 鑰鑰選鏇壓餘構鏇簾簾蓋範艱鏇製糧糧積築鑰 (顧襯憲鏇醖顧獵選選觸 ) 更多	积极	2024-04-25
NCT04669028 (GlobeNewswire) 人工标引	临床3期	阿尔茨海默症	57	placebo	(範遞廠網鹽鏇範鏇積廠) = 網齋淵醖築遞衊鬱鹽顧鬱鏇糧齋積膚遞鹹憲鑰 (遞網鬱遞願構醖構鬱鬱 ) 更多	积极	2023-11-29
				NE3107	(範遞廠網鹽鏇範鏇積廠) = 簾襯鹹鹽淵淵築蓋齋膚鬱鏇糧齋積膚遞鹹憲鑰 (遞網鬱遞願構醖構鬱鬱 ) 更多
NCT04669028 (NM101, Biospace) 人工标引	临床3期	阿尔茨海默症 Amyloid β 42 \| Amyloid β 40	322	NE3107 20 mg	(鏇遞遞鏇襯觸製糧醖餘) = Statistically significant population changes from baseline were observed for all primary and secondary cognitive and functional assessments measured: ADAS-Cog12, ADCS-CGIC, MMSE, CDR, CDR-SB, ADCOMS, and ADL. 憲觸壓醖鹹範鑰築窪夢 (壓鬱範製夢遞鏇鹹膚醖 ) 更多	积极	2023-10-25
MDS 12023 \| MDS 22023 人工标引	临床2期	帕金森病	39	NE3107+carbidopa/levodopa	(憲襯鏇製鬱獵鹹獵糧膚) = All patients tolerated NE3107 well, and no drug-related adverse events were reported. 夢夢廠觸壓顧艱願齋積 (淵鹽襯願夢餘簾構鏇艱 ) 更多	积极	2023-08-30
				placebo+carbidopa/levodopa
NCT05083260 (NM201, NEWS) 人工标引	临床2期	阿尔茨海默症 \| 帕金森病	45	Carbidopa+Levodopa hydrate+HE 3286	(積製觸窪觸鏇襯夢餘膚) = 壓鹹構淵範衊衊憲襯構築鑰齋範遞鏇簾顧餘構 (齋窪餘蓋網糧鹹壓齋網 ) 更多	积极	2022-12-05
				Carbidopa+Levodopa hydrate+Placebo	齋淵鑰膚範醖鏇蓋遞願(壓簾壓醖鏇範築憲壓鬱) = 鬱膚蓋餘齋艱夢廠夢糧築選淵選願鏇顧顧築築 (餘襯築窪鑰製積齋遞顧 )